Your Immune System Is Not Confused | The Angry Gut, Chapter 16

Visceral adiposity · screening beyond BMI

Visceral Adiposity: Screening for the Risk That BMI Misclassifies

Body mass index sorts patients by size. Visceral adiposity sorts them by risk, and in patients with normal weight, diabetes or inflammatory bowel disease the two sortings disagree often enough to change the workup.

Visceral adiposity is the risk variable most primary care charts never record, because the instrument in the room is a scale. Your Immune System Is Not Confused, the video for The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, places the visceral depot inside a broader argument: fat is an immune tissue, and a chronic immune load can originate in the mesentery as readily as in the mucosa. For primary care, endocrine, cardiology and geriatric practices the screening questions are concrete. What does visceral fat add beyond body mass index, which patients carry the most misclassified risk, and what does a finding change?

Is visceral fat a better risk measure than BMI?

I spent years reading a normal weight as a normal metabolic answer. The imaging and tissue data are what corrected that. In a community cohort of 3,086 participants, 49% women with a mean age of 50.2 years, the hazard ratios attached to imaged visceral adipose tissue were 1.44 for incident cardiovascular disease and 1.43 for cancer, independent of body mass index. Adding it to a model already containing body mass index improved cardiovascular prediction modestly, net reclassification improvement 16.3%. No depot predicted all-cause mortality, but that null rests on 71 deaths over a median of 5.0 years and cannot carry a mortality conclusion.

In omental biopsies from 90 women treated surgically for endometrial cancer, adipocyte size correlated with visceral adipose tissue at r = 0.60, and crown-like structures appeared in 48% of samples, associated with diabetes rather than body mass index. In human fat, adipocyte size predicted macrophage infiltration at r² = 0.86 against 0.43 for body mass index. The position here is settled: depot beats mass. Visceral fat that expands out of proportion becomes immunogenic, and a normal-weight patient carrying it is not lean.

Why is visceral fat more harmful than subcutaneous fat?

Omental fat drains to the liver. In 25 extremely obese subjects sampled during bariatric surgery, portal vein interleukin-6 ran about 50% above radial artery levels; flow was not measured, so these are concentrations rather than delivered quantities. The causal test exists only in mice: identical fat grafts produced impaired glucose tolerance and hepatic insulin resistance when placed to drain portally, not systemically, and grafts from IL-6 knockout donors produced neither.

The cytokine that leaves fat is not the one most clinicians name. Across a subcutaneous bed in 39 subjects, venous IL-6 exceeded arterial more than 2-fold while TNF-alpha did not change. In paired explants, visceral tissue released more vascular endothelial growth factor, IL-6 and plasminogen activator inhibitor 1 than abdominal subcutaneous tissue, and the size-related rise in release came from nonfat cells.

One disagreement deserves a sentence. A study of obese women found greater CD11c-positive macrophage density in subcutaneous than omental fat; a surgical series found twice the macrophage burden in omental fat, correlated with fasting glucose, insulin and liver enzymes. The two differ in markers counted, and both support the point that matters for screening: location and cell size carry information that weight does not.

Who should be screened for visceral adiposity?

Normal body mass index with discordant metabolic markers. Elevated fasting glucose or triglycerides, hepatic steatosis, or a strong family history of diabetes.
South Asian patients. In 514 South Asians and 669 Europeans aged 56-86, visceral fat tracked diabetes and coronary disease while thigh muscle was protective, and neither fully explained the excess. Among 264 men assessed with the hyperinsulinemic clamp and MRI fat volumes, insulin sensitivity was lowest in the South Asian group, compared with Chinese and Malay participants, most clearly at lower body size, and fat partitioning did not account for the difference. Muscle belongs in the measurement as much as fat.
Type 2 diabetes and fatty liver, where omental macrophage burden tracks the same laboratory values used to manage them.
Inflammatory bowel disease, particularly Crohn’s disease, where metabolic terrain is rarely charted alongside the biologic.

The social driver belongs in the history. A subsidized food supply built on acellular carbohydrate and industrial seed oil loads this depot years before the scale moves, and the metaflammation it produces reaches the second brain and the vasculature as well as the first brain.

What should change when visceral adiposity is found?

Cytokine suppression does not repair the depot. Etanercept in 56 subjects with metabolic syndrome lowered C-reactive protein with no change in body composition or insulin sensitivity. Six months in 40 obese subjects improved fasting glucose and left body composition, lipids, CRP and IL-6 unchanged. Salsalate in 286 patients with type 2 diabetes lowered HbA1c by 0.37% while weight and LDL cholesterol rose. Canakinumab in 10,061 post-infarction patients reduced events at a hazard ratio of 0.85 without lowering mortality, and fatal infections rose. A trimmed marker is not a repaired terrain.

A finding therefore redirects management upstream, toward diet composition, sleep, activity and behavior, decided by the treating physician, with body composition and metabolic labs repeated to show whether the depot and its downstream values move. The missing human experiment is a trial that reduces visceral fat without weight loss and measures clamp insulin sensitivity; until it exists, serial measurement in the individual patient is the practical substitute.

Can visceral fat testing help in Crohn’s disease?

In Crohn’s disease the depot becomes local. Live bacteria were cultured from mesenteric fat in 9 of 11 Crohn’s patients and in 4 of 4 controls; the organisms differed, not their presence, and the creeping fat behaves as a barrier. Measura [Cardiometabolic and Autonomic Health Analysis] does not diagnose or monitor Crohn’s disease and adds nothing to calprotectin, endoscopy or drug-level monitoring. What it adds is terrain: bioimpedance body composition to separate fat mass from lean mass and follow both, and laboratory panels for glucose, insulin, lipids, liver enzymes and inflammatory markers. With anti-TNF loss of response at 20.9% per patient-year, a metabolic baseline taken while the biologic is working is worth having before it stops.

Documentation and workflow

These measurements fit existing structures. A standing order can attach body composition and a fasting metabolic panel to the triggers above, so screening does not depend on memory. The annual wellness visit is a natural point to record body composition beside weight, and serial results support value-based care documentation. The full evidence file is the companion deep dive for The Angry Gut. The patient-facing explanation is how to measure visceral fat, and schedule-driven metabolic risk is covered in screening shift workers for circadian misalignment. For older hypertensive patients, a waist-to-weight ratio has been tested directly against incident stroke; see weight-adjusted waist index and stroke risk screening.

Frequently asked questions

Does visceral adiposity add prognostic value beyond body mass index?

Modestly, and in a clinically useful direction. In a cohort of 3,086 participants, imaged visceral fat predicted cardiovascular disease and cancer after adjustment for body mass index, with a net reclassification improvement of 16.3% for cardiovascular risk. Mortality was not predicted, but the cohort recorded only 71 deaths, too few to settle that question. Read the clinical rationale.

Is bioimpedance a substitute for CT or MRI quantification of visceral fat?

No. CT and MRI image the visceral compartment directly. Bioimpedance estimates fat mass and lean mass and is best used to characterize muscle and fat together and to follow change in the same patient. Where imaging already exists for another indication, the visceral description in the report is worth retrieving. See guidance on interpreting the report.

Should anti-inflammatory therapy be used to treat inflamed visceral fat?

The human trials argue against expecting it to work. Etanercept lowered C-reactive protein without changing body composition or insulin sensitivity, salsalate lowered HbA1c while weight and LDL cholesterol rose, and canakinumab reduced cardiovascular events without reducing mortality. Suppressing the signal has not repaired the depot in any of them. See what changes for the patient.

Can Measura be used to monitor Crohn’s disease activity?

No. Disease activity belongs to calprotectin, endoscopy and the gastroenterologist. Measura documents the metabolic terrain in patients with inflammatory bowel disease, body composition and laboratory markers of insulin resistance and inflammation, and returns results to the ordering physician for coordination with the treating team. Review specialty applications.

Which normal-weight patients warrant body composition testing?

Those whose metabolic markers disagree with their weight: elevated fasting glucose or triglycerides, fatty liver, or a family history of diabetes. South Asian patients deserve a lower threshold, because visceral fat and thigh muscle each contributed to excess diabetes and coronary risk in that population. See the selection criteria.

Can skinny people have high visceral fat?

Yes. Weight and body mass index cannot see where fat is stored. In omental biopsies, dying fat cells ringed by immune cells went with diabetes, not with body mass index, and fat cell size predicted immune-cell crowding far better than body mass index did. South Asian patients carry more visceral fat and less thigh muscle for their size. A normal-weight patient carrying this depot is not lean.

How do you get rid of visceral adiposity?

Work upstream, not on the inflammation number. Drugs that suppressed inflammatory signals lowered markers such as C-reactive protein but left body composition and insulin sensitivity unchanged. Management moves to diet composition, sleep, activity and behavior, decided by the treating physician. Repeat body composition and metabolic labs to show whether the depot and its downstream values move, because no trial has yet reduced visceral fat without weight loss and measured insulin sensitivity directly.

What are the worst foods for visceral fat?

Acellular carbohydrate and industrial seed oil. A subsidized food supply built on both loads the visceral depot years before the scale moves, which is one reason a normal weight gives false reassurance. The metaflammation that depot produces reaches the gut, the brain and the blood vessels. Diet composition belongs in the history and in the plan, with body composition and metabolic labs repeated to track the response.

Add body composition to your metabolic screening

Learn how the Measura protocol brings body composition and metabolic laboratory measurement into a practice’s existing screening and documentation workflow.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Britton, K. A., Massaro, J. M., Murabito, J. M., Kreger, B. E., Hoffmann, U., & Fox, C. S. (2013). Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. Journal of the American College of Cardiology, 62(10), 921-925. https://doi.org/10.1016/j.jacc.2013.06.027
van den Bosch, A. A. S., Kooreman, L., van de Weijer, T., Romano, A., Brecheisen, R., Jin, X., Delvoux, B., Kruitwagen, R. F. P. M., Pijnenborg, J. M. A., & Werner, H. M. J. (2026). Visceral adipose tissue inflammation in endometrial cancer. Cancer Treatment and Research Communications, 48, 101273. https://doi.org/10.1016/j.ctarc.2026.101273
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56(4), 1010-1013. https://doi.org/10.2337/db06-1656
Rytka, J. M., Wueest, S., Schoenle, E. J., & Konrad, D. (2011). The portal theory supported by venous drainage-selective fat transplantation. Diabetes, 60(1), 56-63. https://doi.org/10.2337/db10-0697
Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S., & Coppack, S. W. (1997). Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. The Journal of Clinical Endocrinology and Metabolism, 82(12), 4196-4200. https://doi.org/10.1210/jcem.82.12.4450
Parvaresh Rizi, E., Teo, Y., Leow, M. K., Venkataraman, K., Khoo, E. Y., Yeo, C. R., Chan, E., Song, T., Sadananthan, S. A., Velan, S. S., Gluckman, P. D., Lee, Y. S., Chong, Y. S., Tai, E. S., Toh, S. A., & Khoo, C. M. (2015). Ethnic Differences in the Role of Adipocytokines Linking Abdominal Adiposity and Insulin Sensitivity Among Asians. The Journal of Clinical Endocrinology and Metabolism, 100(11), 4249-4256. https://doi.org/10.1210/jc.2015-2639
Eastwood, S. V., Tillin, T., Wright, A., Mayet, J., Godsland, I., Forouhi, N. G., Whincup, P., Hughes, A. D., & Chaturvedi, N. (2014). Thigh fat and muscle each contribute to excess cardiometabolic risk in South Asians, independent of visceral adipose tissue. Obesity (Silver Spring, Md.), 22(9), 2071-2079. https://doi.org/10.1002/oby.20796
Bernstein, L. E., Berry, J., Kim, S., Canavan, B., & Grinspoon, S. K. (2006). Effects of etanercept in patients with the metabolic syndrome. Archives of Internal Medicine, 166(8), 902-908. https://doi.org/10.1001/archinte.166.8.902
Goldfine, A. B., Fonseca, V., Jablonski, K. A., Chen, Y. D., Tipton, L., Staten, M. A., & Shoelson, S. E. (2013). Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Annals of Internal Medicine, 159(1), 1-12. https://doi.org/10.7326/0003-4819-159-1-201307020-00003
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., … Glynn, R. J. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine, 377(12), 1119-1131. https://doi.org/10.1056/NEJMoa1707914